{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:55:10Z","timestamp":1793876110509,"version":"4.7.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA077598"],"award-info":[{"award-number":["P30CA077598"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biostatistics and Bioinformatics Core"},{"DOI":"10.13039\/100011539","name":"Masonic Cancer Center, University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1TR004405"],"award-info":[{"award-number":["UM1TR004405"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brain metastases in patients with breast cancer (BCBM) are common. While the Breast Graded Prognostic Assessment (Breast GPA) predicts overall survival (OS), its ability to predict intracranial progression-free survival (icPFS) has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, multi-institutional cohort study to evaluate the association between Breast GPA and icPFS among BCBM patients treated initially with stereotactic radiosurgery (SRS) or whole-brain radiation therapy (WBRT). icPFS was defined as the time from initial local BCBM treatment to the first local salvage treatment or death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 2263 patients, 49% received SRS and 51% WBRT. Subtypes included hormone receptor (HR)+\/HER2\u2212 (31%), HR+\/HER2+ (21%), HR\u2212\/HER2+ (17%), and triple-negative breast cancer (TNBC) (24%). The median icPFS ranged from 6 months (TNBC) to 12 months (HR+\/HER2+). By Breast GPA, the median icPFS ranged from 5 months (GPA 0.0-1.0) to 13 months (GPA 3.5-4.0), and the median OS ranged from 6 to 37 months, respectively. The bias-corrected c-index for Breast GPA was 0.606 for icPFS and 0.648 for OS. icPFS and OS were strongly correlated (r\u2009=\u20090.783; 95% confidence interval, 0.739-0.836). In multivariable analysis, breast cancer subtype, number of BCBM, and Karnofsky Performance Status were the strongest icPFS predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Breast GPA predicts OS and icPFS in BCBM patients, providing valuable benchmarks for clinical trial design. These data establish historical controls for icPFS by subtype and Breast GPA and may guide systemic therapy prioritization in patients at greatest risk of early intracranial progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag102","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:46:23Z","timestamp":1778240783000},"page":"2030-2040","source":"Crossref","is-referenced-by-count":1,"title":["Intracranial progression-free survival correlates with overall survival and varies by tumor subtype in patients with breast cancer and brain metastases"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2589-9422","authenticated-orcid":false,"given":"Sarah L","family":"Sammons","sequence":"first","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Cancer Institute , Boston, MA,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-5466","authenticated-orcid":false,"given":"Ryan","family":"Shanley","sequence":"additional","affiliation":[{"name":"Biostatistics Core, Masonic Cancer Center, University of Minnesota , Minneapolis, MN,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-4074","authenticated-orcid":false,"given":"Carey K","family":"Anders","sequence":"additional","affiliation":[{"name":"Duke Cancer Center , Durham, NC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-5413","authenticated-orcid":false,"given":"Nancy U","family":"Lin","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Dana-Farber Cancer Institute , Boston, MA,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-7161","authenticated-orcid":false,"given":"Paul W","family":"Sperduto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Duke University School of Medicine , Durham, NC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026080501522448600_noag102-B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/EDBK_175338","article-title":"Breast cancer in the central nervous system: multidisciplinary considerations and management","volume":"37","author":"Lin","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026080501522448600_noag102-B2","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/jnci\/djaf048","article-title":"Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients","volume":"117","author":"Sammons","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026080501522448600_noag102-B3","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026080501522448600_noag102-B4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.breast.2014.06.009","article-title":"Metastatic breast cancer subtypes and central nervous system metastases","volume":"23","author":"Aversa","year":"2014","journal-title":"Breast"},{"key":"2026080501522448600_noag102-B5","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026080501522448600_noag102-B6","doi-asserted-by":"publisher","first-page":"e2225424","DOI":"10.1001\/jamanetworkopen.2022.25424","article-title":"Analysis of rates of brain metastases and association with breast cancer subtypes in Ontario, Canada","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026080501522448600_noag102-B7","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-18-2366","article-title":"Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERs","volume":"25","author":"Hurvitz","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026080501522448600_noag102-B8","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"key":"2026080501522448600_noag102-B9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/cncr.20418","article-title":"The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma","volume":"101","author":"Lai","year":"2004","journal-title":"Cancer"},{"key":"2026080501522448600_noag102-B10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026080501522448600_noag102-B11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11060-013-1083-9","article-title":"The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer","volume":"112","author":"Sperduto","year":"2013","journal-title":"J Neurooncol"},{"key":"2026080501522448600_noag102-B12","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"2026080501522448600_noag102-B13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"key":"2026080501522448600_noag102-B14","doi-asserted-by":"publisher","first-page":"102324","DOI":"10.1016\/j.ctrv.2021.102324","article-title":"Targeting brain metastases in breast cancer","volume":"103","author":"Corti","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026080501522448600_noag102-B15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/jco.2011.29.15_suppl.581","article-title":"Salvage stereotactic radiosurgery (SRS) after previous whole-brain radiation therapy (WBRT) for breast cancer brain metastases: outcomes and prognostic factors including tumor phenotype","volume":"29","author":"Kelly","year":"2011","journal-title":"JCO"},{"key":"2026080501522448600_noag102-B16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3171\/2016.5.JNS153051","article-title":"Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery","volume":"127","author":"McKay","year":"2017","journal-title":"J Neurosurg"},{"key":"2026080501522448600_noag102-B17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijrobp.2013.10.003","article-title":"Salvage radiosurgery for brain metastases: prognostic factors to consider in patient selection","volume":"88","author":"Kurtz","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080501522448600_noag102-B18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-015-0028-8","article-title":"Breast cancer brain metastases: the last frontier","volume":"4","author":"Leone","year":"2015","journal-title":"Exp Hematol Oncol"},{"key":"2026080501522448600_noag102-B19","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026080501522448600_noag102-B20","doi-asserted-by":"publisher","first-page":"e2310117","DOI":"10.1001\/jamanetworkopen.2023.10117","article-title":"Intracranial and extracranial progression and their correlation with overall survival after stereotactic radiosurgery in a multi-institutional cohort with brain metastases","volume":"6","author":"Carpenter","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026080501522448600_noag102-B21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijrobp.2020.01.051","article-title":"Beyond an updated graded prognostic assessment (breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today","volume":"107","author":"Sperduto","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080501522448600_noag102-B22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/biom.13453","article-title":"Nonparametric estimation of Spearman\u2019s rank correlation with bivariate survival data","volume":"78","author":"Eden","year":"2022","journal-title":"Biometrics"},{"key":"2026080501522448600_noag102-B23","doi-asserted-by":"crossref","DOI":"10.1201\/b11826","volume-title":"Flexible Imputation of Missing Data","author":"Buuren Sv","year":"2012","edition":"1st"},{"key":"2026080501522448600_noag102-B24","doi-asserted-by":"publisher","first-page":"e479-486","DOI":"10.1016\/j.ijrobp.2012.01.054","article-title":"Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases","volume":"83","author":"Dyer","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080501522448600_noag102-B25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-021-03735-5","article-title":"Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases","volume":"152","author":"Mills","year":"2021","journal-title":"J Neurooncol"},{"key":"2026080501522448600_noag102-B26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10549-020-05835-8","article-title":"Impact of breast cancer subtype on clinical outcomes after Gamma Knife radiosurgery for brain metastases from breast cancer: a multi-institutional retrospective study (JLGK1702)","volume":"184","author":"Aoyagi","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026080501522448600_noag102-B27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S1470-2045(22)00015-8","article-title":"Progression-free survival: it is time for a new name","volume":"23","author":"Gyawali","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026080501522448600_noag102-B28","article-title":"Which matters more? Progression-free survival vs. overall survival","author":"Gevorgyan","year":"2026","journal-title":"Oncodaily"},{"key":"2026080501522448600_noag102-B29","author":"Gutman","year":"2013"},{"key":"2026080501522448600_noag102-B30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.annonc.2024.08.2347","article-title":"A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases","volume":"35","author":"Andre","year":"2024","journal-title":"Ann Oncol"},{"key":"2026080501522448600_noag102-B31","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"2026080501522448600_noag102-B32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026080501522448600_noag102-B33","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.14694\/EdBook_AM.2015.35.e99","article-title":"Whole-brain radiotherapy and stereotactic radiosurgery in brain metastases: what is the evidence?","volume":"35","author":"Mehta","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026080501522448600_noag102-B34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag102\/68273111\/noag102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/8\/2030\/68273111\/noag102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/8\/2030\/68273111\/noag102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:52:30Z","timestamp":1785909150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/8\/2030\/8676475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag102","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,12]]}}}